Corbus Pharmaceuticals, Inc.

110 articles about Corbus Pharmaceuticals, Inc.

• Corbus To Present At Two Upcoming Investor Conferences In December 2015

  11/24/2015

• Corbus Reports 2015 Third Quarter Financial Results

  11/13/2015

• Corbus Announces FDA Orphan Drug Designation And Fast Track Status Of ResunabFor The Treatment Of Cystic Fibrosis

  10/20/2015

• Corbus Announces First Patient Dosed In Phase 2 Study Of Resunab For Treatment Of Cystic Fibrosis

  10/15/2015

• Corbus To Present At The 14th Annual BIO Investor Forum

  10/14/2015

• Corbus Announces First Patient Dosed In Phase 2 Study Of Resunab For Systemic Sclerosis

  10/7/2015

• Corbus To Present Additional Data On The Effects Of Resunab In The Treatment Of Pulmonary Infection And Inflammation In Pre-Clinical Models Of Cystic Fibrosis

  9/22/2015

• Corbus Commences Patient Enrollment In Phase 2 Clinical Study Of Resunab For The Treatment Of Cystic Fibrosis

  9/21/2015

• Corbus Commences Patient Enrollment In Phase 2 Clinical Study Of Resunab For The Treatment Of Systemic Sclerosis

  8/31/2015

• Corbus Successfully Completes Warrant Call -- Raises $11.3 Million In Total From 100% Exercise Of Callable Warrants

  8/28/2015

• Corbus' Investigational Drug Resunab Granted Fast Track Status By The U.S. FDA For The Treatment Of Systemic Sclerosis

  8/19/2015

• Vertex's Success Spurs Startups Corbus and Pulmatrix to Enter Cystic Fibrosis Market

  8/18/2015

• Corbus Reports 2015 Second Quarter Financial Results And Provides Business Update

  8/13/2015

• Corbus To Present At The Canaccord Genuity Growth Conference On August 13, 2015

  8/7/2015

• Corbus Announces Call Notice For Exercise Of Warrants

  7/29/2015

• Corbus Announces Dosing Of First Patient In Phase II Clinical Trial Of Resunab For The Treatment Of Dermatomyositis

  7/13/2015

• Corbus To Present At The JMP Securities Life Sciences Conference On June 23, 2015

  6/18/2015

• Corbus Announces Inclusion In Russell MicroCap Index

  6/16/2015

• Day in the Life of a CEO—Yuval Cohen, Corbus

  6/12/2015

• Corbus Announces FDA Orphan Drug Designation For Resunab For The Treatment Of Systemic Sclerosis (Scleroderma)

  6/12/2015